Welcome to the Alexion area, we are happy to have you here!

Just a quick note that as a visitor to our virtual booth, the following information will be shared with Alexion – first / last name, country and e-mail. These data do not contain sensitive or special categories of personal data.

We may use your Personal Data to contact you to arrange a visit to inform you about Alexion’s area of expertise, diseases and products. 

When visiting our virtual booth, your Personal Data first / last name, country and e-mail will be stored in our database and processed by Alexion for the following purposes: linking your name to attending the Alexion Virtual Booth at ERA-EDTA 2020; or for potentially contacting you to provide further information on the disease; or to invite you to future relevant events.

Please read our full Data Privacy Notice.

Would you like to be contacted in the future about relevant Alexion events or with information relating to your area of interest?

Before ticking the box, please read carefully our Data Privacy Notice and if you agree, please tick the box for being contacted in the future about relevant Alexion events or with information relating to your area of interest:

DISCLAIMER
This material is the intellectual property of Alexion Pharmaceuticals, and are protected under copyright laws. All rights reserved. The views and opinions expressed herein are not necessarily representative of those held by Alexion Pharmaceuticals and the content should not be considered as a substitute for medical or treatment advice. Alexion Pharmaceuticals hereby excludes all liability for misuse of information. This material was prepared for Healthcare Professionals attending ERA-EDTA virtual congress from June 6 to July 9, originally scheduled to take place in Italy. Soliris® (eculizumab) is granted marketing authorization in Europe for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS).